Alrestatin

Alrestatin

Alrestatin is a compound notable for its role as an aldose reductase inhibitor (ARI). Aldose reductase is an enzyme implicated in various complications associated with diabetes mellitus, inclusive of diabetic neuropathy. While Alrestatin presented promise in addressing some of the challenges posed by diabetes, its journey from synthesis to clinical trials was marked by significant challenges.

Synthesis and Historical Background

The inception of Alrestatin dates back to 1969 when it was first synthesized. Pioneering the field of aldose reductase inhibitors, Alrestatin was the inaugural ARI with demonstrable oral bioavailability that transitioned into clinical trial phases. These trials, carried out mainly in the latter part of the 1970s and the early 1980s, sought to evaluate its therapeutic potential.

Clinical Trials and Challenges

Although Alrestatin showed potential as an innovative solution to counteract some diabetic complications, its journey through clinical trials was fraught with setbacks. A significant fraction of these trials was characterized by limited quality, undermining the confidence in the resultant data.

Moreover, the clinical evaluation of Alrestatin was marred by a pronounced incidence of adverse effects. The most concerning of these was hepatotoxicity, a potentially grave liver injury. Such adverse effects, in conjunction with the shortcomings in trial design and data, culminated in the decision to discontinue its development.

Consequently, Alrestatin never progressed to clinical use, thereby limiting its potential to benefit patients with diabetes-related complications.

Structural Relationship and Comparison

Alrestatin shares structural kinship with another aldose reductase inhibitor named tolrestat. Tolrestat's trajectory was a brief commercial one; post its introduction to the market, it had a limited run and was eventually withdrawn in 1997. Despite their structural similarities, both compounds faced challenges that hindered their long-term potential in clinical settings.

Concluding Remarks

Alrestatin, in its time, represented hope for addressing complications of diabetes mellitus, particularly diabetic neuropathy. Its inhibition of aldose reductase marked a novel approach to managing such complications. However, concerns about trial quality and notable adverse effects, especially hepatotoxicity, halted its journey from research to bedside. While Alrestatin's clinical development may have concluded, its role in the history of diabetic treatment and as a precursor to other ARIs ensures its place in the annals of pharmacological research.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

Comprehensive list of medications or pharmaceutical drugs used in the United States with their NDC or national drug code, brand name, dosage, forms of administration etc. sorted alphabetically.

• Top 200 drugs
• Medicare drugs
• Canadian drugs
• Dictionary of drugs
• Encyclopedia of drugs
• List of FDA approved drugs
• List of drugs A-Z - sorted in multipage format
• Drug categories
• Drug dosage forms
• Habit forming drugs

External links

The following is the collection of detailed information and links to the National Institute of Health (NIH) comprehensive drug information portal and other reliable sources of information. Select the drug name below to show drug description, drug classification, other common drug names, and information on the reasons why prescribed, how medication should be used, and what possible side effects could occur.

Drug names

A • B • C • D • E • F • G • H • I • J • K • L • M • N • O • P • Q • R • S • T • U • V • W • X • Y • Z

Search for other drug names not listed above